 |
|
Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis
Zhanhai Li, PhD;
Michael R. Kosorok, PhD;
Philip M. Farrell, MD, PhD;
Anita Laxova, BS;
Susan E. H. West, PhD;
Christopher G. Green, MD;
Jannette Collins, MD;
Michael J. Rock, MD;
Mark L. Splaingard, MD
JAMA. 2005;293:581-588.
Context Although Pseudomonas aeruginosa is the most common virulent respiratory pathogen in cystic fibrosis (CF), the longitudinal development of P aeruginosa infection and its effect on antibody responses and lung disease progression in children with CF remain unclear.
Objective To prospectively examine the epidemiology of P aeruginosa infection and its impact on CF pulmonary morbidity.
Design, Setting, and Patients We prospectively evaluated 56 CF patients at 2 CF centers in Madison and Milwaukee, Wis, from birth up to age 16 years between April 15, 1985, and April 15, 2004, with diagnoses made through the Wisconsin CF Neonatal Screening Project.
Main Outcome Measures Timing of nonmucoid P aeruginosa and mucoid P aeruginosa acquisition was assessed by first positive result. Longitudinal development from no P aeruginosa to nonmucoid P aeruginosa and from nonmucoid P aeruginosa to mucoid P aeruginosa was examined. Outcome measurements included antibody titers, respiratory symptoms, quantitative chest radiography, and pulmonary function tests.
Results Sixteen patients (29%) acquired nonmucoid P aeruginosa in the first 6 months of life. The age-specific prevalence of mucoid P aeruginosa increased markedly from age 4 to 16 years. Nonmucoid and mucoid P aeruginosa were acquired at median ages of 1.0 and 13.0 years, respectively. In contrast with the short transition time from no P aeruginosa to nonmucoid P aeruginosa, the transition time from nonmucoid to mucoid P aeruginosa was relatively long (median, 10.9 years) and could be slightly extended by brief/low anti–P aeruginosa antibiotic treatment. Antibody titers increased with both transitions, but the deterioration in cough scores, chest radiograph scores, and pulmonary function correlated best with transition from nonmucoid to mucoid P aeruginosa.
Conclusions Early prevention and detection of nonmucoid and mucoid P aeruginosa are critical because of early acquisition and prevalence. There is a window of opportunity for suppression and possible eradication (by aggressive anti–P aeruginosa treatment) of initial nonmucoid P aeruginosa. Mucoid P aeruginosa plays a much greater role in CF lung disease progression than nonmucoid P aeruginosa. Antibody titers, cough scores, and chest radiographs are early signs of nonmucoid P aeruginosa and especially mucoid P aeruginosa stages.
Author Affiliations: Departments of Pediatrics (Drs Li, Kosorok, Farrell, Green, and Rock and Ms Laxova), Biostatistics/Medical Informatics (Drs Li and Kosorok), Pathobiological Sciences (Dr West), and Radiology (Dr Collins), University of Wisconsin, Madison; and Department of Pediatrics, Medical College of Wisconsin, Milwaukee (Dr Splaingard).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intensive Care Management of the Patient With Cystic Fibrosis
Kremer et al.
J Intensive Care Med 2008;23:159-177.
ABSTRACT
Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis
Jarad and Giles
Chronic Respiratory Disease 2008;5:29-33.
ABSTRACT
Multiple-Locus Variable-Number Tandem-Repeat Analysis for Longitudinal Survey of Sources of Pseudomonas aeruginosa Infection in Cystic Fibrosis Patients
Vu-Thien et al.
J. Clin. Microbiol. 2007;45:3175-3183.
ABSTRACT
| FULL TEXT
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Mayer-Hamblett et al.
Proc Am Thorac Soc 2007;4:370-377.
ABSTRACT
| FULL TEXT
Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
Sagel et al.
Proc Am Thorac Soc 2007;4:406-417.
ABSTRACT
| FULL TEXT
Radiological and functional changes over 3 years in young children with cystic fibrosis
Terheggen-Lagro et al.
Eur Respir J 2007;30:279-285.
ABSTRACT
| FULL TEXT
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients
Doring et al.
Proc. Natl. Acad. Sci. USA 2007;104:11020-11025.
ABSTRACT
| FULL TEXT
Resistance to Pseudomonas aeruginosa Chronic Lung Infection Requires Cystic Fibrosis Transmembrane Conductance Regulator-Modulated Interleukin-1 (IL-1) Release and Signaling through the IL-1 Receptor
Reiniger et al.
Infect. Immun. 2007;75:1598-1608.
ABSTRACT
| FULL TEXT
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss and Burns
Thorax 2007;62:360-367.
ABSTRACT
| FULL TEXT
Surfactant Protein A2 (SP-A2) Variants Expressed in CHO Cells Stimulate Phagocytosis of Pseudomonas aeruginosa More than Do SP-A1 Variants
Mikerov et al.
Infect. Immun. 2007;75:1403-1412.
ABSTRACT
| FULL TEXT
Aspergillus fumigatus Generates an Enhanced Th2-Biased Immune Response in Mice with Defective Cystic Fibrosis Transmembrane Conductance Regulator
Allard et al.
J. Immunol. 2006;177:5186-5194.
ABSTRACT
| FULL TEXT
Early Pulmonary Manifestation of Cystic Fibrosis in Children With the {Delta}F508/R117H-7T Genotype
O'Sullivan et al.
Pediatrics 2006;118:1260-1265.
ABSTRACT
| FULL TEXT
Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis
Kappler et al.
Thorax 2006;61:684-688.
ABSTRACT
| FULL TEXT
Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population
Tramper-Stranders et al.
Thorax 2006;61:689-693.
ABSTRACT
| FULL TEXT
Pseudomonas serology: confusion, controversy, and challenges
Farrell and Govan
Thorax 2006;61:645-647.
FULL TEXT
Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity To Eradicate Bacteria
Starner and McCray
ANN INTERN MED 2005;143:816-822.
FULL TEXT
Adaptations of Pseudomonas aeruginosa to the Cystic Fibrosis Lung Environment Can Include Deregulation of zwf, Encoding Glucose-6-Phosphate Dehydrogenase
Silo-Suh et al.
J. Bacteriol. 2005;187:7561-7568.
ABSTRACT
| FULL TEXT
Otopathogenic Pseudomonas aeruginosa Strains as Competent Biofilm Formers
Wang et al.
Arch Otolaryngol Head Neck Surg 2005;131:983-989.
ABSTRACT
| FULL TEXT
Early Immune Response to the Components of the Type III System of Pseudomonas aeruginosa in Children with Cystic Fibrosis
Corech et al.
J. Clin. Microbiol. 2005;43:3956-3962.
ABSTRACT
| FULL TEXT
Development of mucoid Pseudomonas aeruginosa coincides with pulmonary deterioration in cystic fibrosis
Derry
Thorax 2005;60:334-334.
FULL TEXT
|
